89Bio

89bio Unveils Bullish Long-Term Data for NASH Candidate
89bio Unveils Bullish Long-Term Data for NASH Candidate
BioSpace
89Bio
NASH
clinical trials
pegozafermin
Flag link:
EASL 2023 – Biomarkers back a new NASH player
EASL 2023 – Biomarkers back a new NASH player
EP Vantage
NASH
89Bio
pefozafermin
Boston Pharmaceuticals
BOS-580
Flag link:
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
Flag link:
89Bio Enlivened by Nash success
89Bio Enlivened by Nash success
EP Vantage
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
Flag link:
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Endpoints
89Bio
NASH
clinical trials
gozafermin
Akero Therapeutics
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
89bio to initiate Phase III trials for pegozafermin in severe hypertriglyceridaemia
89bio to initiate Phase III trials for pegozafermin in severe hypertriglyceridaemia
Clinical Trials Arena
89Bio
pegozafermin
clinical trials
hypertriglyceridemia
Flag link:
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
89bio’s home run fails to excite
89bio’s home run fails to excite
EP Vantage
89Bio
NASH
pegozafermin
hypertriglyceridemia
Flag link:
89bio gains a little more confidence in NASH treatment with new hormone data
89bio gains a little more confidence in NASH treatment with new hormone data
Fierce Biotech
89Bio
NASH
liver disease
pegozafermin
Flag link:
Teva spinout delays NASH IPO while Galera prices below range
Teva spinout delays NASH IPO while Galera prices below range
Endpoints
Teva Pharmaceutical
89Bio
Galera
IPOs
Flag link:
Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles
Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles
Endpoints
IPOs
Galera Therapeutics
89Bio
Centogene
Flag link:
89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team
89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team
CP WIre
89Bio
NASH
NAFLD
clinical trials
Flag link:
89Bio starting Proof of Concept Trial for NASH therapy and announcing expansion of leadership team
89Bio
NASH
NAFLD
clinical trials
Flag link:
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding
89Bio Joins NASH Chase with a Teva Drug and $60M in Funding
Xconomy
89Bio
Teva Pharmaceutical
NASH
Flag link: